Funding Momentum POP's SNAP platform has attracted CEPI support and is advancing toward a Phase I trial, signaling near-term demand for development services, regulatory strategy, and manufacturing readiness to bring a vaccine candidate to the clinic.

Grant-Driven Programs NIH and STTR funding for mosaic immunotherapy programs indicates a multi-program pipeline with translational potential; sales opportunities include preclinical to IND-enabling services, biomarker development, regulatory consulting, and grant-focused program management.

Collaborative Vaccine Active collaboration with EuBiologics on shingles vaccine demonstrates openness to co-development and licensing; target opportunities include joint development arrangements, regional manufacturing support, supply chain services, and licensing of SNAP platform technology.

Outsourced R&D Small team size implies reliance on outsourced expertise; sales opportunities exist for CRO/CDMO augmentation, process development, analytical testing, quality systems support, and program management to accelerate timelines.

Regional Growth Base in Buffalo with ongoing funding activity positions POP to become a regional biotech hub; opportunities to engage with local universities, state incentives, and early-stage biotech customers for partnerships, equipment provisioning, and services to support vaccine and immunotherapy programs.